Peer-reviewed veterinary case report
Benazepril treatment effects on cats with chronic kidney failure
By Watanabe, Toshifumi & Mishina, Mika·Published in The Journal of veterinary medical science·2007·Department of Surgery, Japan·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Effects of benazepril hydrochloride in cats with experimentally induced or spontaneously occurring chronic renal failure.
- Species:
- cat
Plain-English summary
A group of cats with chronic kidney disease (CRF) were treated with a medication called benazepril hydrochloride to see if it could help manage their symptoms. The treatment was given daily for several weeks, and it successfully lowered high blood pressure and reduced levels of harmful substances in their blood. In another group of cats with naturally occurring CRF, benazepril also helped lower their kidney-related blood values and protein in their urine. Overall, the medication showed promise in improving kidney health and managing hypertension in cats with CRF.
People also search for: cat kidney disease treatment · benazepril for cats · chronic renal failure in cats · cat high blood pressure symptoms
Abstract
We examined effects of an angiotensin converting-enzyme inhibitor, benazepril hydrochloride (BH), on renal hypertension and chronic renal failure (CRF) in cats. For experimental CRF, healthy cats (n=5) underwent 7/8 renal ablation. After renal insufficiency and hypertension were confirmed by blood urea nitrogen (BUN), serum creatinine, creatinine clearance and telemetric recording of systemic blood pressure, BH was administered orally once daily at 0.9 to 2.0 mg/kg/day for 2 to 3 weeks. Within 2 months after renal ablation, renal failure and hypertension developed as evidenced by significant increases in BUN, serum creatinine and systemic blood pressure (p<0.01 or 0.05) and significantly decreased creatinine clearance accompanied by elevated plasma renin activity, angiotensin I and II, and aldosterone (p<0.01 or 0.05). BH administration corrected systemic hypertension (p<0.05) and significantly reduced angiotensin II and aldosterone (p<0.05). Upon discontinuation of BH, these values returned to the pre-administration levels. Studies on spontaneous CRF enrolled 11 cats with spontaneously occurring CRF. BH was administered orally to 6 cats once daily for 24 weeks at a final dose of 1.0 mg/kg/day, while 5 cats served as control. BH administration reduced serum creatinine and urinary protein concentration in every cat. Results demonstrate that in cats, loss of renal mass leads to activation of the renin-angiotensin-aldosterone system and associated renal hypertension, and indicate that BH is effective in correcting renal hypertension and may provide renal benefits to cats with CRF.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/17984588/